April 24, 2024 11:08 AM EDTUpdated 11:57 AM

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Jared Whitlock

Features Editor

Lia DeGroot

Almost 20 biopharma and life sciences companies have registered to lobby on a bill that could ban US companies from working with Chinese life sciences …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Jared Whitlock

Features Editor

Lia DeGroot

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Features Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues